The research report categorizes the market into the following segments and subsegments: Real World Evidence Market, By Therapeutic Area. - 31)    4.1 Real-World Evidence: Market Overview     4.2 Europe Real-World Evidence Market, By Therapeutic Area and Country     4.3 Market: Geographic Snapshot     4.4 Real-World Evidence: Geographic Mix, 5 Real World Evidence Solutions Market: Overview (Page No. Global top 2000 strategist rely on us for their growth strategies. The large share of this segment can be attributed to the increasing importance of RWE studies in drug approvals, the need to prevent costly drug recalls, and the increasing need to assess drug performance in real-world settings. - 55)    8.1 Introduction     8.2 Oncology     8.3 Cardiovascular Disease     8.4 Neurology     8.5 Immunology     8.6 Other Therapeutic Areas, 9 Real World Evidence Solutions Market: By End User (Page No. ©2020 MarketsandMarkets Research Private Ltd. All rights reserved, Published Date: Jul 2018 | Report Code: HIT 6444. However, the reluctance to rely on real-world studies and the lack of universally accepted methodological standards for data collection some of the factors limiting the growth of this market during the forecast period. The base year considered for the study is 2017 and the forecast period includes 2018 to 2023. Top-down and bottom-up approaches were used to validate the size of Real World Evidence Solutions industry and estimate the size of other dependent submarkets. Presence of a favorable regulatory environment, high number of RWE service providers, the presence of a well-established pharmaceutical industry in the region, coupled with the high R&D expenditure, are the major factors responsible for the large share of North America in the global real world evidence market. Request for detailed methodology, assumptions & how numbers were triangulated. - 63)    9.1 Introduction     9.2 Pharmaceutical & Medical Device Companies     9.3 Healthcare Payers     9.4 Healthcare Providers     9.5 Other End Users, 10 Real World Evidence Solutions Market: By Region (Page No. 80% of fortune 2000 companies rely on our research to identify new revenue sources. IQVIA has registered significant growth serving providers, payers and the biopharmaceutical services industry, and has a presence in all major markets, including the US, Japan, Germany, France, Spain, and Italy, in addition to Brazil, Russia, India, and China (BRIC countries). The breakdown of profiles of primaries is shown in the figure below: The prominent players in the global real world evidence market are IQVIA (US), International Business Machines Corporation (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), Cognizant (US), Oracle (US), SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US). Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. Primary sources such as experts from both supply and demand sides have been interviewed to obtain and validate information as well as to assess dynamics of this market. To increase its geographic presence and customer base, the company focused on mergers and acquisitions as a key growth strategy. Information & discussion on the relevant new products and services, Information & discussion on Market insights and Market information, Information & discussion on our events and conferences, Professional and social network (Linkedin, etc), Communication and Connectivity Technology, Coatings Adhesives Sealants and Elastomers, Automotive Electronics and Electrical Equipment, Construction Technology and Sustainability, ACCESS REsearch insights on KNOWN AND UNKNOWN ADJACENCIES ON Healthcare IT, Analytical and Scientific Instrumentation, To define, describe, and forecast the global real-world evidence market on the basis of component, therapeutic area, end user, and region, To provide detailed information regarding the major factors influencing the growth of the real world evidence solutions market (drivers, restraints, opportunities, and industry-specific challenges), To strategically analyze micromarkets with respect to the individual growth trends, future prospects, and contributions to the overall market, To analyze the opportunities in the real world evidence solutions market for stakeholders and provide details of the competitive landscape for market leaders, To forecast the size of the market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and the Rest of the World, along with major countries in these regions, To strategically profile the key players and comprehensively analyze their market shares and core competencies in the real-world evidence market, To track and analyze competitive developments such as partnerships, agreements, & collaborations; alliances; mergers & acquisitions; and new service launches in the global real world evidence solutions market, Pharmaceutical and medical device companies, Pharmaceutical and Medical Device Companies, Detailed analysis and profiling of additional market players (Up to 5), Further breakdown of the European market into Sweden, Denmark and Netherland, Further breakdown of the Asia Pacific market into South Korea and Australia, Get Data as per your Format and Definition, Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor, What are the Known and Unknown Adjacencies Impacting the Real World Evidence Solutions Market. The global real-world evidence market is valued at 612.0 million in 2017 and projected to … [157 Pages Report] Real-world evidence is the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from the analysis of real-world data. - 35)    5.1 Introduction     5.2 Market Dynamics            5.2.1 Drivers                    5.2.1.1 Rising Geriatric Population and the Subsequent Increase in the Prevalence of Chronic Diseases                    5.2.1.2 Shift From Volume- to Value-Based Care                    5.2.1.3 Delays in Drug Development and the Subsequent Increase in Development Costs           5.2.2 Restraints                    5.2.2.1 Reluctance to Rely on Real-World Studies           5.2.3 Opportunities                    5.2.3.1 Growth Opportunities in Emerging Markets                    5.2.3.2 Rising Focus on End-To-End Rwe Services           5.2.4 Challenges                    5.2.4.1 Lack of Universally Accepted Methodological Standards and Data Processing Infrastructure, 6 Industry Trends (Page No. - 111)     11.1 Overview      11.2 Competitive Scenario              11.2.1 Mergers & Acquisitions             11.2.2 Partnerships, Agreements, Alliances, and Collaborations             11.2.3 Services Launches, 12 Company Profiles (Page No. - 45)    7.1 Introduction     7.2 Data Sets            7.2.1 Clinical Settings Data           7.2.2 Claims Data           7.2.3 Pharmacy Data           7.2.4 Patient-Powered Data    7.3 Services, 8 Real World Evidence Solutions Market: By Therapeutic Area (Page No.